Announced Wed, 19 Aug · 09:00 IST
NATCO Pharma files August 2026 investor presentation
Order Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDFExplain this filing
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.1%1-day move
₹897.30
prior close
₹898.95
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4+0.5+0.9+0.5-2.1-1.6————————
Up moveDown movePending
AI summary
NATCO Pharma filed its August 2026 investor presentation. FY26 revenue fell to INR 43,759 crore from INR 47,840 crore, with net profit at INR 14,185 crore versus INR 18,834 crore. EBITDA margin slipped to 39.6 percent from 53.3 percent. Q1FY27 revenue fell to INR 7,944 crore from INR 13,906 crore year on year. Board has approved demerger of the Crop Health Sciences division. Pipeline includes 28 Para IVs and 30 plus products in development.
Likely market impact
FY26 earnings declined and Q1FY27 revenue dropped sharply. CHS demerger and product pipeline progress are positive triggers.